Click here to download our corporate presentation
BIOPHYTIS is a biotechnology company created in 2006, specialising in diseases associated with aging, particularly those affecting muscular and visual functions.
Aging science
By understanding the relationship between natural active substances and degeneration processes BIOPHYTIS is able to identify families of substances capable of acting directly on the mechanism of the disease.
BIOPHYTIS has a portfolio of first-in-class drug candidates, at various stages of development, for treating certain indications of sarcopenia and AMD, for which there is currently no treatment.
16 May 2018

Results of the 2018 Annual Meeting of Shareholders. Read the Press Release

15 May 2018

Biophytis receives Orphan Drug Designation from the FDA for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release